KR20240130848A - Cosmetic composition for strengthening skin barrier and improving skin disease containing NMN and fermented product of human-derived complex strains - Google Patents

Abstract

The present invention relates to a cosmetic composition for strengthening the skin barrier and improving skin diseases, comprising NMN (Nicotinamide Mononucleotide) and a fermented product of a human-derived complex strain.

Description

{Cosmetic composition for strengthening skin barrier and improving skin disease containing NMN and fermented product of human-derived complex strains}

The present invention relates to a cosmetic composition for strengthening the skin barrier and improving skin diseases, comprising NMN (Nicotinamide Mononucleotide) and a fermented product of a human-derived complex strain.

The skin is largely divided into three layers: the epidermis, dermis, and subcutaneous fat, and functions to protect the human body from physical and chemical stimuli from the external environment. In particular, the skin transports about 65–70% of the moisture in the human body, i.e., various physiologically active substances necessary for the human body, and helps maintain the skin in a soft and moist state. In addition, the epidermis is divided into the stratum corneum, granular layer, spinous layer, and basal layer in that order from the outside. The cells of the stratum corneum act like bricks, and the intercellular lipids between the keratinocytes act like mortar to form the skin barrier (J. Invest. Dermatol. 80(Suppl.), 44-49. 1983). The stratum corneum of the epidermis contains about 10–20% of moisture and is located at the outermost layer of the human body, suppressing moisture evaporation from the body while blocking excessive penetration of substances from the outside. The surface of these stratum corneum is covered with a thin natural protective film made of sebum from the sebaceous glands and sweat from the sweat glands, which prevents moisture evaporation. The cells that make up the stratum corneum of the skin contain a high concentration of natural moisturizing factor (NMF), a water-soluble component, which acts to make the skin flexible and helps maintain appropriate moisture. For example, substances such as amino acids are not only water-soluble but also effectively bind to moisture, preventing the skin from drying out (J. Invest. Dermatol. 54, 24-31, 1970).

However, due to various reasons such as artificial temperature control due to changes in the environment or lifestyle, skin stress due to various stresses and environmental pollution arising from social life, frequent washing due to makeup habits, and natural skin aging due to aging, the moisture in the stratum corneum decreases, causing the skin to become dry, the surface to become rough, and the skin to lose its luster and look dull. Therefore, the need for skin moisturizers is increasing.

Meanwhile, the most widely used method for maintaining skin moisture is to increase moisture retention in the stratum corneum by using occlusive moisturizers that prevent moisture evaporation. However, these have the disadvantage of feeling sticky or wet when applied to the skin due to the unique viscosity and physical properties of polyol. In addition, existing skin moisturizers can cause skin troubles, so there are problems with skin safety. Therefore, there is a need to develop a skin moisturizer that is more stable and has an excellent moisturizing effect.

Against the background described above, the inventors of the present invention have made great efforts to develop a cosmetic composition for strengthening the skin barrier and improving skin diseases, and as a result, have confirmed that when NMN and a fermented product of human-derived complex strains are used in the manufacture of a cosmetic composition, not only is the composition excellent in biocompatibility, but also has a skin moisturizing effect and an itching-improving effect, thereby completing the present invention.

The present invention discloses a cosmetic composition, a pharmaceutical composition and a health functional food composition for strengthening the skin barrier and improving skin diseases, which contain NMN (Nicotinamide Mononucleotide) and a fermented product of a human-derived complex strain as effective ingredients.

In the present invention, the skin disease may be any one selected from skin inflammation, eczema, contact dermatitis, atopic dermatitis, seborrheic dermatitis, lichen simplex chronicus, intertrigo, exfoliative dermatitis, papular urticaria, psoriasis, psoriatic arthritis, solar dermatitis, sunburn, and acne.

In the present invention, the content of NMN may be 0.1 to 2 wt% relative to the entire cosmetic composition.

In the present invention, the human-derived complex bacterial strain fermentation product may be Bacillus subtilis, Bacillus coagulans, Bacillus clausii, or any combination thereof.

In the present invention, the content of the human-derived complex bacterial strain fermentation product in the cosmetic composition may be 1,000 to 50,000 ppm.

In the present invention, the cosmetic composition further comprises an avocado peptide, a vitamin, alpha-arbutin, or any combination thereof, and the vitamin may comprise vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3, and vitamin A.

In the present invention, the cosmetic composition further comprises 0.1 to 2 wt% of avocado peptide, 0.1 to 2 wt% of vitamin, and 0.1 to 2 wt% of alpha-arbutin relative to the total cosmetic composition, and the vitamin may include vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3, and vitamin A.

In the present invention, when the composition is a cosmetic composition, the formulation may be one or more selected from the group consisting of a toner (skin lotion), a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisture lotion, a nutrition lotion, a massage cream, a nutrition cream, an eye cream, a moisture cream, a hand cream, a foundation, an essence, a nutrition essence, a pack, a soap, a cleansing foam, a cleansing lotion, a cleansing cream, a body lotion, and a body cleanser.

The composition containing NMN and human-derived complex strain according to the present invention as active ingredients is expected to be effectively used as a cosmetic composition, a health functional food composition, and a pharmaceutical composition since it exhibits excellent effects in increasing skin hydration, alleviating itching, and improving skin diseases.

Meanwhile, the scope of the present invention is not limited by the effects described above.

Figure 1 shows the results of a cytotoxicity test of a cosmetic composition according to the present invention.

Hereinafter, a cosmetic composition for strengthening the skin barrier and improving skin diseases, including NMN and a fermented human-derived complex strain according to a specific embodiment of the present invention, will be described in detail. However, this is merely an example for illustration, and the scope of the present invention is not limited thereto, and it is obvious to those skilled in the art that various modifications to the examples are possible within the scope of the present invention.

The terms "include" or "comprise" as used herein, unless otherwise stated throughout this specification, mean the inclusion of a particular configuration (or element) without limitation, and cannot be construed as excluding the addition of other configurations (or elements).

The term "skin" as used herein refers to the tissue covering the body surface of an animal, and is a broad concept that includes not only the tissue covering the body surface such as the face or body, but also the scalp and hair.

The term "skin moisturizing" as used herein means maintaining moisture in the stratum corneum of the skin and preventing the skin from drying out or having a rough surface by inhibiting evaporation of moisture from the skin and blocking excessive penetration of external substances, thereby allowing the skin to remain soft and moist.

The term "itchy skin" as used herein means an unpleasant sensation that causes a desire to scratch or rub the skin, and includes, as examples, itching due to dry skin; itching due to hives; itching due to insect bites; itching caused by heat rash, acne, scabies, frostbite, contact dermatitis, seborrheic dermatitis, or psoriasis; itching due to various skin diseases; itching of the scalp, etc. However, it should be understood that the present invention does not exclude various causes of itching other than the itching listed above. The present invention includes all itching known in the art, for example, itching due to dermatological causes, itching due to systemic causes, itching due to neuropathic causes, and itching due to psychogenic causes.

The term “skin disease” as used herein may include, without limitation, a skin disease causing an allergic or inflammatory reaction occurring in the skin, and may be, for example, any one skin disease selected from skin inflammation, eczema, contact dermatitis, atopic dermatitis, seborrheic dermatitis, lichen simplex chronicus, intertrigo, exfoliative dermatitis, papular urticaria, psoriasis, psoriatic arthritis, solar dermatitis, sunburn, and acne, and preferably, atopic dermatitis, which is a chronic intractable allergic or inflammatory skin disease.

The terms “improvement” or “treatment” as used herein mean (a) inhibition of the development, (b) alleviation, and (c) elimination of a dermatitis condition in a subject.

The term "prevention" as used herein means inhibiting the occurrence of a disease or condition in a subject who has not been diagnosed as having the disease or condition, but is predisposed to developing such disease or condition.

Ⅰ. Cosmetic composition

The present invention aims to provide a cosmetic composition for strengthening the skin barrier and improving skin diseases, which contains NMN (Nicotinamide Mononucleotide) and a fermented product of a human-derived complex strain as effective ingredients.

In the cosmetic composition according to the present invention, the content of NMN is 0.1 to 2 wt% based on the entire cosmetic composition, and preferably 1 to 1.5 wt%. If the NMN is less than 0.1 wt% based on the entire cosmetic composition, the effects of improving wrinkles, elasticity, and pores may be poor, and if the NMN exceeds 2 wt% based on the entire cosmetic composition, the effects may be poor compared to the content, which may not be economical.

In the cosmetic composition according to the present invention, the human-derived complex bacterial strain fermentation product may include, but is not limited to, Bacillus subtilis, Bacillus coagulans, Bacillus clausii, or any combination thereof.

In the cosmetic composition according to the present invention, the content of the human-derived complex strain fermentation product is 1,000 to 50,000 ppm, preferably 5,000 to 30,000 ppm, and more preferably 10,000 to 20,000 ppm in the cosmetic composition. If the concentration of the human-derived complex strain fermentation product is less than 1,000 ppm, it is difficult to obtain the desired wrinkle, elasticity, and pore improvement effects, and if it exceeds 50,000 ppm, there is a problem that the production economy is reduced because no significant increase in effect is observed as the content increases.

In the cosmetic composition according to the present invention, the cosmetic composition may further contain an avocado peptide, in which case the content of the avocado peptide may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the cosmetic composition according to the present invention, the cosmetic composition may further include vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3, vitamin A or any combination thereof, and in this case, the content of the vitamin may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the cosmetic composition according to the present invention, the cosmetic composition may further contain alpha-albutin, in which case the content of the vitamin may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the cosmetic composition according to the present invention, the cosmetic composition may further include avocado peptide, vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3, vitamin A, and alpha-albutin.

The cosmetic composition according to the present invention can be applied as a gel type, skin type, cream type, ointment type, etc., but is not limited thereto. The above composition can be appropriately prepared by a known method by adding an appropriate conventional softener, emulsifier, thickener, or other materials known in the art according to its type.

The gel type composition according to the present invention can be manufactured by adding a softener such as trimethylolpropane, polyethylene glycol or glycerin, a solvent such as propylene glycol, ethanol or isocetyl alcohol, a purified water, etc.

The skin type composition according to the present invention can be prepared by adding fatty alcohols such as stearyl alcohol, myristyl alcohol, behenyl alcohol, arachidyl alcohol, isostearyl alcohol, and isocetyl alcohol; butylene glycol, glycerin, allantoin, methyl paraben, sodium EDTA-2, xanthan gum, dimethicone, polyethylene glycol-60 hydrogenated castor oil, polysorbate 60, and purified water.

The cream type composition according to the present invention can be manufactured by adding fatty alcohols such as stearyl alcohol, myristyl alcohol, behenyl alcohol, arachidyl alcohol, isostearyl alcohol, and isocetyl alcohol; lipids such as lecithin, phosphatidylcholine, phosphatidylethanolamine, sophatidylserine, and sophatidyl inositol; derivatives thereof; emulsifiers such as glyceryl stearate, sorbitan palmitate, and sophatidyl stearate; natural fats or oils such as avocado oil, apricot oil, babassu oil, gromwell oil, and camellia oil; solvents such as propylene glycol; and purified water.

The ointment type composition according to the present invention can be manufactured by adding a softener, an emulsifier, and a wax such as microcrystalline wax, paraffin, ceresin, beeswax, spermaceti, and vaseline.

The cosmetic composition according to the present invention may additionally contain one or more skin barrier strengthening and skin disease improving ingredients having the same or similar functions as the effective ingredient. In addition, the cosmetic composition of the present invention may additionally contain excipients including fluorescent substances, fungicides, hydrotropism inducers, moisturizers, fragrances, fragrance carriers, proteins, solubilizers, sugar derivatives, sunscreens, vitamins, plant extracts, etc.

The cosmetic composition according to the present invention can be formulated as a softening toner, an astringent toner, a nourishing toner, an eye cream, a serum, a nourishing cream, a massage cream, a cleansing cream, a cleansing lotion, a cleansing foam, cleansing water, a powder, an essence, a pack, a hair tonic, a hair treatment, a shampoo or a rinse.

The cosmetic composition according to the present invention can be formulated by a conventional method. For the formulation of a skin external preparation, reference may be made to the contents disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, and for the formulation of a cosmetic composition, reference may be made to the contents disclosed in International cosmetic ingredient dictionary, 6th ed (The Cosmetic, Toiletry and Fragrance Association, Inc, Washington, 1995). Specifically, the cosmetic composition can be prepared as a general emulsified formulation and a solubilized formulation. For example, the cosmetic composition can be prepared as a toner such as an emollient toner or a nourishing toner; an emulsion such as a facial lotion or a body lotion; a cream such as a nourishing cream, a moisture cream, or an eye cream; an essence; a cosmetic ointment; a spray; a gel; a pack; a sunscreen; a makeup base; a foundation such as a liquid type, a solid type, or a spray type; a powder; a makeup remover such as a cleansing cream, a cleansing lotion, or a cleansing oil; Or, it may be formulated as a cleansing agent such as a cleansing foam, soap, or body wash, but is not limited thereto. In addition, the skin external preparation may be formulated as an ointment, patch, gel, cream, or spray, but is not limited thereto.

In the cosmetic composition according to the present invention, in addition to the above essential ingredients, other ingredients may be appropriately blended in each formulation, depending on the type of formulation or intended use, within a range that does not impede the purpose of the present invention.

The cosmetic composition according to the present invention may include a conventionally acceptable carrier, and may appropriately mix, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc., but is not limited thereto.

The acceptable carrier according to the present invention may vary depending on the formulation. For example, when formulated as an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or mixtures thereof may be used as the carrier component.

When the cosmetic composition according to the present invention is formulated as a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, and in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane, butane or dimethyl ether may be further included.

When the cosmetic composition according to the present invention is formulated as a solution or emulsion, a solvent, a solubilizer, or an emulsifier can be used as a carrier component, and for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil can be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan can be used.

When the cosmetic composition according to the present invention is formulated as a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used as a carrier component.

The cosmetic composition according to the present invention may additionally contain adjuvants commonly used in the field of cosmetology or dermatology, such as fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestering agents, chelating agents, preservatives, blocking agents, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, and any other ingredients commonly used in cosmetics, depending on the quality or function of the final product. However, the adjuvants and the mixing ratio thereof may be appropriately selected so as not to affect the desirable properties of the cosmetic composition according to the present invention.

Ⅱ. Food composition

The present invention aims to provide a health functional food composition for strengthening the skin barrier and improving skin diseases, which contains NMN (Nicotinamide Mononucleotide) and a fermented product of a human-derived complex strain as effective ingredients.

In the health functional food composition according to the present invention, the content of NMN is 0.1 to 2 wt% based on the entire health functional food composition, and preferably 1 to 1.5 wt%. If the NMN is less than 0.1 wt% based on the entire cosmetic composition, the wrinkle, elasticity, and pore improvement effects may be low, and if the NMN exceeds 2 wt% based on the entire cosmetic composition, the effect may be low compared to the content, making it uneconomical.

In the health functional food composition according to the present invention, the human-derived complex bacterial strain fermentation product may include, but is not limited to, Bacillus subtilis, Bacillus coagulans, Bacillus clausii, or any combination thereof.

In the health functional food composition according to the present invention, the content of the human-derived complex strain fermentation product is 1,000 to 50,000 ppm, preferably 5,000 to 30,000 ppm, and more preferably 10,000 to 20,000 ppm in the health functional food composition. If the concentration of the human-derived complex strain fermentation product is less than 1,000 ppm, it is difficult to obtain the desired wrinkle, elasticity, and pore improvement effects, and if it exceeds 50,000 ppm, there is a problem that the production economy is low because no significant increase in effect is observed as the content increases.

In the health functional food composition according to the present invention, the health functional food composition may further contain an avocado peptide, and in this case, the content of the avocado peptide may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the health functional food composition according to the present invention, the health functional food composition may further include vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3, vitamin A or any combination thereof, and in this case, the content of the vitamin may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the health functional food composition according to the present invention, the health functional food composition may further contain alpha-albutin, in which case the content of the vitamin may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the health functional food composition according to the present invention, the health functional food composition may further include avocado peptide, vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3, vitamin A, and alpha-albutin.

There is no particular limitation on the type of the health functional food composition according to the present invention, and it may be in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, etc., or may be added to general foods such as candies, cookies, gum, ice cream, noodles, bread, and beverages.

The health functional food of the present invention can be manufactured by suitably using food-related carriers such as fillers, bulking agents, binders, humectants, disintegrants, sweeteners, flavoring agents, preservatives, surfactants, lubricants, and excipients, depending on the form, in a conventional manner.

Ⅲ. Pharmaceutical Composition

The present invention aims to provide a pharmaceutical composition for strengthening the skin barrier and improving skin diseases, which contains NMN (Nicotinamide Mononucleotide) and a fermented product of a human-derived complex strain as effective ingredients.

In the pharmaceutical composition according to the present invention, the content of NMN is 0.1 to 2 wt% based on the total cosmetic composition, and preferably 1 to 1.5 wt%. If the content of NMN is less than 0.1 wt% based on the total cosmetic composition, the effects of improving wrinkles, elasticity, and pores may be poor, and if the content of NMN exceeds 2 wt% based on the total cosmetic composition, the effects may be poor compared to the content, which may not be economical.

In the pharmaceutical composition according to the present invention, the human-derived complex strain fermentation product may include, but is not limited to, Bacillus subtilis, Bacillus coagulans, Bacillus clausii, or any combination thereof.

In the pharmaceutical composition according to the present invention, the content of the human-derived complex strain fermentation product is 1,000 to 50,000 ppm, preferably 5,000 to 30,000 ppm, and more preferably 10,000 to 20,000 ppm in the cosmetic composition. If the concentration of the human-derived complex strain fermentation product is less than 1,000 ppm, it is difficult to obtain the desired wrinkle, elasticity, and pore improvement effects, and if it exceeds 50,000 ppm, there is a problem that the production economy is low because no significant increase in effect is observed as the content increases.

In the pharmaceutical composition according to the present invention, the pharmaceutical composition may further contain an avocado peptide, in which case the content of the avocado peptide may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the pharmaceutical composition according to the present invention, the pharmaceutical composition may further contain vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3, vitamin A or any combination thereof, in which case the content of the vitamin may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the pharmaceutical composition according to the present invention, the pharmaceutical composition may further contain alpha-albutin, in which case the content of the vitamin may be 0.1 to 2 wt%, preferably 0.5 to 1 wt%, relative to the entire cosmetic composition.

In the pharmaceutical composition according to the present invention, the pharmaceutical composition may further contain avocado peptide, vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3, vitamin A, and alpha-albutin.

The pharmaceutical composition according to the present invention includes dermal, oral, intravenous, intramuscular, intraarterial, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration, and oral or parenteral administration is preferred but not limited thereto. The parenteral administration includes subcutaneous, intradermal, intravenous, intramuscular and intralesional injection or infusion techniques.

The pharmaceutical composition according to the present invention may additionally contain one or more active ingredients having the same or similar function as the composition according to the present invention. The composition may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods.

The solid preparations for oral administration of the pharmaceutical composition above include powders, granules, tablets, capsules, soft capsules, pills, etc. The liquid preparations for oral administration include suspensions, solutions, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. The preparations for parenteral administration can be formulated and used in the form of external preparations such as powders, granules, tablets, capsules, sterilized aqueous solutions, solutions, non-aqueous solvents, suspensions, emulsions, syrups, suppositories, aerosols, etc. and sterile injection preparations according to conventional methods, and preferably, a skin external pharmaceutical composition such as a cream, gel, patch, spray, ointment, warning agent, lotion, liniment agent, paste agent, or cataplasm agent can be prepared and used, but is not limited thereto. Non-aqueous solvents and suspending agents can be used, such as propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases can be used, such as witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin.

The pharmaceutical composition according to the present invention may additionally contain auxiliary agents such as preservatives, stabilizers, wetting agents or emulsifying promoters, salts for osmotic pressure control and/or buffers, and other therapeutically useful substances, and may be formulated by conventional mixing, granulation or coating methods.

The pharmaceutical composition according to the present invention may vary depending on several factors including the age, weight, general health, sex, administration time, administration route, excretion rate, drug combination, and severity of a specific disease of the subject.

When the pharmaceutical composition according to the present invention is formulated in the form of a unit dosage containing the iCP-NI peptide as an active ingredient, it is preferable that the iCP-NI peptide as an active ingredient is contained in a unit dosage of about 0.01 to 1,500 mg, and the dosage required for adult treatment is usually in the range of about 1 to 500 mg per day depending on the frequency and intensity of administration, but is not limited thereto. When administered intramuscularly or intravenously to adults, a single dose of usually about 5 to 300 mg per day will be sufficient, but a higher daily dosage may be desirable for some patients. The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

Hereinafter, the present invention will be described in more detail through examples and experimental examples. However, the following examples and experimental examples are intended to illustrate the present invention, and the content of the present invention is not limited to the following examples and experimental examples.

<Manufacturing Example>

Manufacturing Example 1. Manufacturing of a cosmetic composition containing NMN and fermented human-derived complex strain according to the present invention

Nicotinamide Mononucleotide 1 wt%, Lactobacillus ferment 18,200ppm, Avocado peptides 1 wt%, VITA 10 complex (Vitamin C, Vitamin E, Vitamin B5, Vitamin B12, Vitamin B7, Vitamin B6, Vitamin B9, Vitamin B1, Vitamin B3 and Vitamin A) 1 wt%, Alpha-albutin 1 wt%, 1,3-Butylene glycol 8 wt%, 1,2-Hexanediol 2 wt%, EDTA-2Na 0.02 wt%, Ammonium acryloyldimethyltaurate/VP copolymer 0.5 wt%, Cetearyl alcohol 2.0 wt%, PEG-100 stearate 1.5 wt%, Glyceryl stearate 0.7 wt%, Beeswax 1 wt%, Cetylethylhexanoate 5 wt%, Squalane 3 wt%, A cream containing 2.0 wt% of C14-22 alcohol, 0.5 wt% of Polysorbate 20, 1.2 wt% of Sorbitan isostearate, 0.5 wt% of C12-20 alkylglucoside, 2 wt% of cyclomethicone, 1 wt% of Dimethicone, 0.5 wt% of Dimethiconol, an appropriate amount of FRAGRANCE, and water (balance) was prepared.

<Example>

Example 1. Cytotoxicity test (MTT assay) of cosmetic composition according to the present invention

2 X 10 ⁴ Human NDFB (Normal Dermal Fibroblast) were treated in a 96-well plate for 24 hours before treatment with the test substance, and then cultured in DMEM without FBS + 1% Penicillin/Streptomycin (P/S) to perform cell cycle arrest. Then, the concentration of Nicotinamide Mononucleotide in the cosmetic composition according to Manufacturing Example 1, which is the test substance, was changed to 0, 0.125, 0.25, 0.5, and 1 wt%, respectively, and cultured for 24 hours in DMEM without FBS + 1% P/S medium, and the MTT assay was performed using the MTT assay kit from Invitrogen according to the manufacturer's instructions. The raw data obtained through the ELISA Reader were statistically analyzed using the Repeated Measure One-way ANOVA test of the Graphpad Prism statistical program based on the results obtained through a total of three repeated experiments, and then the significance between the experimental groups was determined through Tukey's Multiple Comparison Test.

As a result, as can be seen from Fig. 1, it was confirmed that the cosmetic composition according to the present invention does not affect the cell viability ratio.

Example 2. Evaluation of the efficacy of a cosmetic composition according to the present invention

The human application test of the cosmetic composition according to the present invention was performed in accordance with the GCP (Good Clinical Practice) guidelines, relevant regulations of the Ministry of Food and Drug Safety (MFDS), and the standard operating procedure (SOP) of Human Skin Clinical Trial Center Co., Ltd. After washing the test area of 20 test subjects with lukewarm water, they waited for more than 30 minutes under constant temperature and humidity conditions (22±2°C, 50±5%) to sufficiently stabilize their skin before participating in the test.

(1) Evaluation of itching efficacy

To evaluate the efficacy of anti-itching, the subjects were asked to rate their own itching on a 10-point scale before and after 4 weeks of using the test product, and the average score was calculated to evaluate the degree of improvement in itching.

Evaluation items Before using the product After 4 weeks of use Significance probability ¹⁾ Improvement rate Itch Score) 4.90±1.81 1.19±1.12 <0.001 75.73%

1) p-value: Significant probability, Wilcoxon signed rank test (p<0.05, comparison to initial value). As can be seen from Table 1 above, it was confirmed that the facial itchiness score was significantly reduced by 75.73% when the cosmetic composition according to Example 1 was used (Fig. 2).

(2) Measurement of skin moisture content

Regarding skin moisture content, skin surface moisture content (ε skin moisture content (A.U.)) and transepidermal water loss (g/m2h) were measured using Epsilon E100 (Biox Systems Ltd., England), Corneometer CM825 Probe (Courage+Khazaka GmbH, Germany), and Vapometer (Delfin Technologies Ltd., Finland), respectively, and the results are shown in Table 2 below.

Evaluation items Before using the product After 4 weeks of use Significance probability ¹⁾ Improvement rate Skin surface moisture content (ε 25.03±6.07 34.43±4.85 <0.001 37.57% Skin moisture content (A.U.) 23.23±5.45 67.19±11.63 <0.001 189.24% Transepidermal water loss (g/m2h) 11.30±2.44 9.48±1.72 <0.001 16.14%

As can be seen from the above Table 2, when the cosmetic composition according to Example 1 was used, the skin surface moisture content (ε) of the cheek area significantly increased by 37.57%, the skin moisture content (A.U.) of the cheek area significantly increased by 189.24%, and the transepidermal water loss (g/m2h) of the cheek area significantly increased by 16.14%.

(3) Evaluation of skin moisturizing efficacy

To evaluate the skin moisturizing efficacy, the deep skin moisture content (TDC) was measured using the XS5 probe (0.5 mm depth) and M25 probe (2.5 mm depth) on one cheek area before and after 4 weeks of using the test product using Moisturemeter D (Delfin Technologies Ltd., Finland).

Evaluation items Before using the product After 4 weeks of use Significance probability ¹⁾ Improvement rate 0.5mm depth 29.94±4.15 34.40±3.53 <0.001 14.88% 2.5mm depth 33.51±2.97 36.90±3.40 <0.001 10.11%

As can be seen from Table 3 above, when the cosmetic composition according to Example 1 was used, the deep skin moisture content (TDC) of the cheek area using the XS5 Probe significantly increased to 14.88%, and the deep skin moisture content (TDC) of the cheek area using the M25 Probe significantly increased to 10.11%.

While the specific parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific descriptions are merely preferred implementation examples and that the scope of the present invention is not limited thereto. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (15)

A cosmetic composition for strengthening the skin barrier and improving skin diseases, containing NMN (Nicotinamide Mononucleotide) and a fermented product of human-derived complex strains as effective ingredients.
In the first paragraph,
A cosmetic composition, characterized in that the skin disease is any one selected from skin inflammation, eczema, contact dermatitis, atopic dermatitis, seborrheic dermatitis, lichen simplex chronicus, intertrigo, exfoliative dermatitis, papular urticaria, psoriasis, psoriatic arthritis, solar dermatitis, sunburn, and acne.
In the first paragraph,
A cosmetic composition, characterized in that the content of the NMN is 0.1 to 2 wt% based on the total cosmetic composition.
In the first paragraph,
A cosmetic composition characterized in that the human-derived complex bacterial strain fermentation product is Bacillus subtilis, Bacillus coagulans, Bacillus clausii, or any combination thereof.
In the first paragraph,
A cosmetic composition, characterized in that the content of the human-derived complex bacterial strain fermentation product in the cosmetic composition is 1,000 to 50,000 ppm.
In paragraph 1,
The cosmetic composition further comprises avocado peptides, vitamins, alpha-arbutin, or any combination thereof.
A cosmetic composition, characterized in that the vitamins include vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3 and vitamin A.
In the first paragraph,
The cosmetic composition further comprises 0.1 to 2 wt% of avocado peptide, 0.1 to 2 wt% of vitamin, and 0.1 to 2 wt% of alpha-arbutin relative to the total cosmetic composition.
A cosmetic composition, characterized in that the vitamins include vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3 and vitamin A.
In the first paragraph,
The formulation of the above cosmetic composition is characterized in that one or more is selected from the group consisting of toner (skin lotion), skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, eye cream, moisture cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser.
A health functional food composition for strengthening the skin barrier and improving skin diseases, containing NMN (Nicotinamide Mononucleotide) and a fermented product of human-derived complex strains as effective ingredients.
In Article 9,
A health functional food composition, characterized in that the skin disease is any one selected from skin inflammation, eczema, contact dermatitis, atopic dermatitis, seborrheic dermatitis, lichen simplex chronicus, intertrigo, exfoliative dermatitis, papular urticaria, psoriasis, psoriatic arthritis, solar dermatitis, sunburn, and acne.
In Article 9,
A health functional food composition, characterized in that the content of the above NMN is 0.1 to 2 wt% based on the total composition.
In Article 9,
A health functional food composition characterized in that the human-derived complex bacterial strain fermentation product is Bacillus subtilis, Bacillus coagulans, Bacillus clausii, or any combination thereof.
In Article 9,
A health functional food composition, characterized in that the content of the human-derived complex bacterial strain fermentation product in the composition is 1,000 to 50,000 ppm.
In Article 9,
The above health functional food composition further comprises avocado peptide, vitamin, alpha-arbutin, or any combination thereof.
A health functional food composition, characterized in that the vitamins include vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3 and vitamin A.
In Article 9,
The above health functional food composition further comprises 0.1 to 2 wt% of avocado peptide, 0.1 to 2 wt% of vitamin, and 0.1 to 2 wt% of alpha-arbutin relative to the total composition.
A health functional food composition, characterized in that the vitamins include vitamin C, vitamin E, vitamin B5, vitamin B12, vitamin B7, vitamin B6, vitamin B9, vitamin B1, vitamin B3 and vitamin A.